APGE Apogee Therapeutics Inc.
Price (delayed)
$39.09
Market cap
$2.33B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.3
Enterprise value
$2.2B
We are a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with
Highlights
The debt has decreased by 2.5% from the previous quarter
APGE's equity has surged by 89% year-on-year but it is down by 2.4% since the previous quarter
The quick ratio has grown by 13% from the previous quarter but it has contracted by 5% YoY
APGE's net income has dropped by 117% year-on-year and by 24% since the previous quarter
The company's EPS fell by 36% QoQ
Key stats
What are the main financial stats of APGE
Market
Valuations
Earnings
Shares outstanding
59.5M
Market cap
$2.33B
Enterprise value
$2.2B
Price to earnings (P/E)
N/A
Price to book (P/B)
3.19
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$216.87M
Net income
-$182.15M
EBIT
-$182.13M
EBITDA
-$180.25M
Free cash flow
-$172.33M
Per share
Balance sheet
Liquidity
EPS
-$3.3
EPS diluted
-$3.3
Free cash flow per share
-$3.12
Book value per share
$12.25
Revenue per share
$0
TBVPS
$13.66
Total assets
$753.95M
Total liabilities
$37.16M
Debt
$11.83M
Equity
$716.79M
Working capital
$501.15M
Debt to equity
0.02
Current ratio
18.55
Quick ratio
18.23
Net debt/EBITDA
0.72
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-23.1%
Return on equity
-24.1%
Return on invested capital
-36%
Return on capital employed
-25.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
APGE stock price
How has the Apogee Therapeutics stock price performed over time
Intraday
1.45%
1 week
10.3%
1 month
7.8%
1 year
-44%
YTD
-13.71%
QTD
-13.71%
Financial performance
How have Apogee Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$216.87M
Net income
-$182.15M
Gross margin
N/A
Net margin
N/A
Apogee Therapeutics's operating income has shrunk by 133% YoY and by 22% QoQ
APGE's net income has dropped by 117% year-on-year and by 24% since the previous quarter
Growth
What is Apogee Therapeutics's growth rate over time
Valuation
What is Apogee Therapeutics stock price valuation
P/E
N/A
P/B
3.19
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS fell by 36% QoQ
APGE's equity has surged by 89% year-on-year but it is down by 2.4% since the previous quarter
APGE's P/B is 19% below its last 4 quarters average of 3.9
Efficiency
How efficient is Apogee Therapeutics business performance
APGE's return on equity has surged by 51% year-on-year but it is down by 11% since the previous quarter
The company's return on invested capital has surged by 50% YoY but it fell by 3.7% QoQ
Apogee Therapeutics's ROA has increased by 24% YoY but it has decreased by 11% from the previous quarter
Dividends
What is APGE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for APGE.
Financial health
How did Apogee Therapeutics financials performed over time
APGE's total assets has surged by 88% year-on-year but it is down by 2.9% since the previous quarter
Apogee Therapeutics's total liabilities has surged by 73% YoY but it has decreased by 11% QoQ
The debt is 98% less than the equity
APGE's debt to equity has soared by 100% YoY
APGE's equity has surged by 89% year-on-year but it is down by 2.4% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.